UY31418A1 - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos - Google Patents

Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos

Info

Publication number
UY31418A1
UY31418A1 UY31418A UY31418A UY31418A1 UY 31418 A1 UY31418 A1 UY 31418A1 UY 31418 A UY31418 A UY 31418A UY 31418 A UY31418 A UY 31418A UY 31418 A1 UY31418 A1 UY 31418A1
Authority
UY
Uruguay
Prior art keywords
preparation
treatment
cognitive disorders
patients affected
human albumin
Prior art date
Application number
UY31418A
Other languages
English (en)
Inventor
Victor Grifols Roura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31418A1 publication Critical patent/UY31418A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion se basa en la utilizacion de albumina humana terapéutica para la preparacion de un medicamento par el tratamiento de pacientes afectados por desordenes cognitivos, en la que el modelo de administracion del medicamento comprende la administracion al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albumina terapéutica humana mediante recambio plasmático y/o perfusion intravenosa, sin dependencia del contenido de AB(Beta) en sangre del paciente.
UY31418A 2007-10-26 2008-10-23 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos UY31418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Publications (1)

Publication Number Publication Date
UY31418A1 true UY31418A1 (es) 2009-05-29

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31418A UY31418A1 (es) 2007-10-26 2008-10-23 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos

Country Status (17)

Country Link
US (1) US7851446B2 (es)
EP (1) EP2111868B1 (es)
JP (1) JP5437619B2 (es)
CN (1) CN101417123B (es)
AR (1) AR068901A1 (es)
AU (1) AU2008233025B8 (es)
BR (1) BRPI0804623B8 (es)
CA (1) CA2641830C (es)
CL (1) CL2008003133A1 (es)
ES (2) ES2332846B1 (es)
HK (1) HK1126689A1 (es)
MX (1) MX2008013635A (es)
NZ (1) NZ572131A (es)
PL (1) PL2111868T3 (es)
PT (1) PT2111868E (es)
RU (1) RU2414925C2 (es)
UY (1) UY31418A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
UA126232C2 (uk) * 2016-08-18 2022-09-07 Алкахест, Інк. Спосіб лікування когнітивного розладу, пов'язаного зі старінням, та набір, що містить фракцію плазми крові
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CA3061194A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2020018343A1 (en) * 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
AU2019364271A1 (en) 2018-10-26 2021-06-03 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
IL307764A (en) * 2021-04-30 2023-12-01 Grifols Worldwide Operations Ltd Use of plasma exchange and low volume plasma exchange to treat cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US7695903B2 (en) 2000-05-23 2010-04-13 The University Of Southern California Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
MXPA05003607A (es) 2002-10-04 2005-11-17 Prana Biotechnology Ltd Compuestos neurologicamente activos.
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
PT1592439E (pt) 2003-02-13 2007-06-22 Octapharma Ag Processo para a preparação de uma solução de albumina
EP1651195A4 (en) 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
BRPI0804623B1 (pt) 2020-02-11
ES2428698T3 (es) 2013-11-08
MX2008013635A (es) 2009-05-11
CA2641830A1 (en) 2009-04-26
EP2111868B1 (en) 2013-08-21
US7851446B2 (en) 2010-12-14
BRPI0804623B8 (pt) 2021-05-25
ES2332846B1 (es) 2010-07-08
JP2009108059A (ja) 2009-05-21
PL2111868T3 (pl) 2014-01-31
EP2111868A1 (en) 2009-10-28
AU2008233025B2 (en) 2013-06-27
RU2008141076A (ru) 2010-04-27
JP5437619B2 (ja) 2014-03-12
AU2008233025B8 (en) 2013-07-25
RU2414925C2 (ru) 2011-03-27
CN101417123A (zh) 2009-04-29
AR068901A1 (es) 2009-12-16
ES2332846A1 (es) 2010-02-12
CN101417123B (zh) 2012-06-27
HK1126689A1 (en) 2009-09-11
CL2008003133A1 (es) 2009-08-07
AU2008233025A1 (en) 2009-05-14
PT2111868E (pt) 2013-10-17
NZ572131A (en) 2010-06-25
US20090111740A1 (en) 2009-04-30
BRPI0804623A2 (pt) 2009-06-30
CA2641830C (en) 2013-07-16

Similar Documents

Publication Publication Date Title
UY31418A1 (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos
BRPI0820800A2 (pt) Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente
JP2013155188A5 (es)
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
WO2008067991A3 (en) Skin-friendly drug complexes for transdermal administration
JP2010518164A5 (es)
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
ECSP077843A (es) Tratamiento o prevención del prurito
AR041891A1 (es) Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza
Nordal Where has all the psychotherapy gone?
EA201170319A1 (ru) Приложение напряжения сдвига для лечения заболеваний
CN114588164A (zh) 瑞马唑仑在预防围术期低体温和寒战中的应用
Periyasami et al. Attai Vidal (Leech Therapy) in Siddha System of Medicine and their current concept in therapeutic application-A Review
Cohen et al. Mebaral in the treatment of epilepsy
Patel et al. Management of Non Healing Ulcer with Local Application of Yastimadhu Ghrita (Glycyrrhiza Glabra L.): A Single Case Study
JP1720531S (ja) 薬液投与器用穿刺具
Boroojeny et al. Effects of oral clonidine as pre-medication on blood pressure in patients under spinal anesthesia
Almomani The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures
JP1720529S (ja) 薬液投与器用穿刺具
CN202105157U (zh) 一种新型内科用外敷中药治疗装置
Van Schoor Colds, flu and coughing: a review of over-the-counter nasal therapies in general practice
JP2016504361A5 (es)
CN2605869Y (zh) 冠心病外用药物护胸袋

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190715